Acadian Asset Management LLC Lowers Stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

Acadian Asset Management LLC lessened its holdings in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) by 98.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,827 shares of the biotechnology company’s stock after selling 951,531 shares during the period. Acadian Asset Management LLC owned about 0.82% of Pieris Pharmaceuticals worth $106,000 as of its most recent filing with the Securities & Exchange Commission.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th.

Insider Buying and Selling at Pieris Pharmaceuticals

In other Pieris Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc bought 3,000 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average price of $15.88 per share, with a total value of $47,640.00. Following the completion of the acquisition, the insider now directly owns 129,574 shares of the company’s stock, valued at $2,057,635.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.89% of the stock is currently owned by insiders.

Pieris Pharmaceuticals Trading Up 1.5 %

Shares of Pieris Pharmaceuticals stock opened at $17.24 on Friday. Pieris Pharmaceuticals, Inc. has a twelve month low of $6.20 and a twelve month high of $27.20. The firm’s 50-day moving average price is $15.66 and its 200 day moving average price is $13.00. The firm has a market capitalization of $22.76 million, a PE ratio of -1.44 and a beta of 0.66.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.